Is it safe for a postpartum woman with a history of depression or anxiety to take Lexapro (escitalopram) while breastfeeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Lexapro (Escitalopram) Use During Breastfeeding

Yes, it is safe to take Lexapro while breastfeeding, with appropriate infant monitoring. Escitalopram is excreted into breast milk at low levels, with breastfed infants receiving only approximately 3.9% of the maternal weight-adjusted dose, which is well below the 10% safety threshold typically considered acceptable for breastfeeding 1.

Key Safety Data

Infant exposure through breast milk is minimal and clinically insignificant:

  • Exclusively breastfed infants receive approximately 3.9% of the maternal weight-adjusted escitalopram dose and 1.7% of the demethylescitalopram (metabolite) dose 1
  • The total relative infant dose is 5.3% as escitalopram equivalents, which is below the 10% safety threshold 2
  • Escitalopram concentrations in infant plasma are typically below detectable levels (≤3 mcg/L) compared to average maternal plasma concentrations of 24 mcg/L 2
  • Median infant plasma exposure is only 1.7% (range 0.5-5.9%) of maternal plasma levels 3

Required Infant Monitoring

The FDA label explicitly requires monitoring for specific adverse effects 1:

  • Excessive sedation or somnolence
  • Restlessness and agitation
  • Poor feeding
  • Poor weight gain

These effects are rare but have been reported in isolated cases with citalopram (the racemic mixture), though most infants show no adverse effects 1, 2.

Clinical Context and Comparative Safety

Escitalopram may actually be preferred over racemic citalopram for breastfeeding mothers:

  • The absolute infant dose of escitalopram is lower than an equivalent antidepressant dose of racemic citalopram 2
  • Research shows escitalopram has a favorable safety profile, with all studied infants meeting normal developmental milestones and showing no adverse effects 2
  • Among SSRIs, paroxetine and sertraline are considered first-line agents for breastfeeding 4, 5, but escitalopram is also considered safe with appropriate monitoring 6

Risk-Benefit Considerations

The developmental and health benefits of breastfeeding must be weighed against the mother's clinical need for treatment 1:

  • Untreated maternal depression poses significant risks to both mother and infant, including negative impacts on infant emotional development 6
  • The degree of severity of maternal depression is the most relevant parameter in deciding whether to continue pharmacological treatment during breastfeeding 6
  • Women already taking escitalopram during pregnancy can safely continue while breastfeeding, as the infant has already had in utero exposure 4

Practical Recommendations

If you are taking Lexapro 10-20 mg daily (standard therapeutic doses):

  • Continue breastfeeding while maintaining your medication 1, 2
  • Monitor your infant closely for the specific adverse effects listed above, particularly in the first few weeks 1
  • Ensure regular pediatric follow-up to track infant weight gain and developmental milestones 2
  • Contact your healthcare provider immediately if you notice excessive sleepiness, feeding difficulties, or inadequate weight gain in your infant 1

Common pitfall to avoid: Do not discontinue effective antidepressant treatment solely due to breastfeeding concerns, as the risks of untreated maternal depression often outweigh the minimal infant drug exposure 6. The decision should prioritize maternal mental health while implementing appropriate infant monitoring protocols.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.